Latest Hotspot

MBX Biosciences declares encouraging data from a Phase 1 Multiple Ascending Dose study for MBX 2109

17 September 2023
3 min read

MBX Biosciences, Inc., a biopharmaceutical firm engaged in clinical trials, released favorable outcomes from the Phase 1 trial's multiple ascending dose section for MBX 2109. This long-acting parathyroid hormone (PTH)) peptide prodrug developed by the company is a type of Precision Endocrine Peptide™ (PEP™) therapies aimed at handling a variety of endocrine disorders, specifically hypoparathyroidism.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

"We're encouraged by the promising data from our Phase 1 study, reinforcing our confidence in the potential advantages of the PEP technology platform," stated MBX Biosciences' CEO and president, Kent Hawryluk. "MBX 2109, our principal product candidate, and a potential market leader in PTH replacement therapy, is geared to progress to the next phase of its development. We are enthusiastically preparing for our Phase 1 conclusion conversation with the FDA later this year."

A total of 76 adults participated in a randomized, double-blind, placebo-controlled Phase 1 clinical trial meant to measure the safety, tolerability, PK and PD of individual and multiple escalating doses of MBX 2109 in healthy adult volunteers. Single and multiple increasing doses of MBX 2109 proved largely acceptable in terms of tolerance with primary and secondary endpoints being safety, tolerability, respective PK and PD parameters.

Hypoparathyroidism, which affects approximately 200,000 people globally, is a rare hormonal disease resulted from an inadequate supply of parathyroid hormone, leading to reduced calcium and amplified phosphorus levels in the bloodstream. Typical triggers of HP are parathyroid gland damage or removal during thyroid surgery. The condition is typified by a wide spectrum of symptoms and comorbidities and the current primary treatment aim is to consistently manage blood calcium levels toward the lower end of the normal spectrum, hence alleviating hypocalcemia symptoms.

The recommended treatment nowadays encompasses high-dose calcium supplementations and active vitamin D, potentially contributing to complications with the kidneys and not targeting the basal pathophysiology induced by a parathyroid hormone deficiency.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

According to the data provided by the Synapse Database, As of September 14, 2023, there are 84 investigational drugs for the PTH1R target, including 31 applicable indications,98 R&D institutions involved, with related clinical trials reaching 386and as many as 826 patents.

MBX 2109 is an investigational long-acting parathyroid hormone peptide prodrug in development as a PTH replacement therapy for hypoparathyroidism. In July 2022, MBX 2109 received Orphan Drug designation from the U.S. Food and Drug Administration for the treatment of hypoparathyroidism. MBX aims to simplify and improve an individual’s disease management, while relieving both the symptoms of the disorder and long-term complications.

图形用户界面, 文本

描述已自动生成

Star of transcriptional pathway potential: CDK9 inhibitor
Star of transcriptional pathway potential: CDK9 inhibitor
17 September 2023
CDK9, also known as cyclin-dependent kinase 9, plays a crucial role in the regulation of gene expression and cell cycle progression in the human body.
Read →
EyePoint Pharmaceuticals releases an encouraging safety update for EYP-1901 under PAVIA and DAVIO 2 Phase 2 Clinical Studies
Latest Hotspot
4 min read
EyePoint Pharmaceuticals releases an encouraging safety update for EYP-1901 under PAVIA and DAVIO 2 Phase 2 Clinical Studies
17 September 2023
EyePoint Pharmaceuticals, Inc., a company focused on improving life quality for severe eye condition patients, has revealed promising safety data for its key product candidate EYP-1901.
Read →
CDK7 inhibitor - potential treatment strategy for multiple tumors
CDK7 inhibitor - potential treatment strategy for multiple tumors
17 September 2023
CDK7 is a member of the cell cycle-dependent kinase (CDK) family, and a subunit of the multiprotein basal transcription factor TFIIH.
Read →
Ifinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trial
Latest Hotspot
3 min read
Ifinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trial
15 September 2023
Updated results from a subgroup analysis of a phase 1/2 trial showed that ifinatamab deruxtecan (I-DXd) continues to demonstrate durable responses in patients with heavily pretreated advanced small cell lung cancer.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.